Fort, L.P. Incyte Corp Transaction History

Fort, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $11,157 - $13,897	218 Added 6.06%	3,817 $231,000
Q1 2024 May 14, 2024	BUY	$56.55 - $66.59 $2,657 - $3,129	47 Added 1.32%	3,599 $205,000
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $3,408 - $3,889	59 Added 1.69%	3,552 $205,000
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $14,079 - $17,442	231 Added 7.08%	3,493 $217,000
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $11,236 - $13,761	-160 Reduced 4.68%	3,262 $235,000
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $229,889 - $287,824	3,422 New	3,422 $274,000
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $109,044 - $160,127	-1,470 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $92,874 - $126,375	1,470 New	1,470 $108,000

652

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Fort, L.P., based on Form 13F filings with the SEC.

Stay updated on Fort, L.P. with notifications on news.